Effect of interleukin 13 on bronchial hyperresponsiveness and the bronchoprotective effect of β-adrenergic bronchodilators and corticosteroids

Robert G. Townley, Pradeep R. Gendapodi, Nidal Qutna, Joseph Evans, Francisco A. Romero, Peter W. Abel

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Fluticasone affects airway bronchial hyperresponsiveness (BHR) and enhances bronchodilation and broncho-protection induced by β-adrenergic agonists. Interleukin 13 (IL-13), however, induces BHR. Objective: To test the hypotheses that fluticasone inhibits BHR after either allergen sensitization or IL-13 administration and that fluticasone restores the bronchodilation and bronchoprotective effects of β-agonists. Methods: The BHR to methacholine induced by IL-13 or ovalbumin was determined in BALB/c mice, and the provocation concentration of methacholine that caused an increase in enhanced pause in expiration of 200% (PC 200) was calculated. We compared this response to methacholine in control mice with the response after treatment with IL-13 receptor α 2-IgGFc fusion protein (IL-13Rα2) (an IL-13 blocker), fluticasone, albuterol, salmeterol, fluticasone-albuterol, and fluticasone-salmeterol. Results: IL-13Rα2 (PC 200, 17.59) completely blocks the BHR-induced effects of IL-13 (PC 200, 7.28; P ≤.005). After IL-13 therapy (PC 200, 5.90; P ≤.005), 1 mg/mL of albuterol (PC 200, 3.38; P =.33), fluticasone (PC 200, 4.59; P =.40), or fluticasone plus 50 μg/mL of salmeterol (PC 200, 5.59; P =.11) showed no significant bronchoprotection. In nonsensitized mice, fluticasone plus 0.25 μg/mL of salmeterol (PC 200, 25.90; P ≤.005) showed significantly greater bronchoprotection than did salmeterol alone (PC 200, 11.08; P =.26). Fluticasone plus 0.3 mg/mL of albuterol and fluticasone plus 1 mg/mL of albuterol were significantly more protective than was fluticasone or albuterol alone in ovalbumin-sensitized mice. Conclusions: The protective effects of fluticasone, βagonists, and fluticasone plus β-agonists are significantly less in IL-13-treated mice than in nonsensitized or ovalbumin-sensitized mice.

Original languageEnglish
Pages (from-to)190-197
Number of pages8
JournalAnnals of Allergy, Asthma and Immunology
Volume102
Issue number3
StatePublished - Mar 2009

Fingerprint

Interleukin-13
Bronchodilator Agents
Adrenergic Agents
Adrenal Cortex Hormones
Albuterol
Methacholine Chloride
Ovalbumin
Interleukin-13 Receptors
Fluticasone
Adrenergic Agonists
Allergens
Proteins

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Effect of interleukin 13 on bronchial hyperresponsiveness and the bronchoprotective effect of β-adrenergic bronchodilators and corticosteroids. / Townley, Robert G.; Gendapodi, Pradeep R.; Qutna, Nidal; Evans, Joseph; Romero, Francisco A.; Abel, Peter W.

In: Annals of Allergy, Asthma and Immunology, Vol. 102, No. 3, 03.2009, p. 190-197.

Research output: Contribution to journalArticle

Townley, Robert G. ; Gendapodi, Pradeep R. ; Qutna, Nidal ; Evans, Joseph ; Romero, Francisco A. ; Abel, Peter W. / Effect of interleukin 13 on bronchial hyperresponsiveness and the bronchoprotective effect of β-adrenergic bronchodilators and corticosteroids. In: Annals of Allergy, Asthma and Immunology. 2009 ; Vol. 102, No. 3. pp. 190-197.
@article{6c7b7c4b428d4f089a29c6418de1e66d,
title = "Effect of interleukin 13 on bronchial hyperresponsiveness and the bronchoprotective effect of β-adrenergic bronchodilators and corticosteroids",
abstract = "Background: Fluticasone affects airway bronchial hyperresponsiveness (BHR) and enhances bronchodilation and broncho-protection induced by β-adrenergic agonists. Interleukin 13 (IL-13), however, induces BHR. Objective: To test the hypotheses that fluticasone inhibits BHR after either allergen sensitization or IL-13 administration and that fluticasone restores the bronchodilation and bronchoprotective effects of β-agonists. Methods: The BHR to methacholine induced by IL-13 or ovalbumin was determined in BALB/c mice, and the provocation concentration of methacholine that caused an increase in enhanced pause in expiration of 200{\%} (PC 200) was calculated. We compared this response to methacholine in control mice with the response after treatment with IL-13 receptor α 2-IgGFc fusion protein (IL-13Rα2) (an IL-13 blocker), fluticasone, albuterol, salmeterol, fluticasone-albuterol, and fluticasone-salmeterol. Results: IL-13Rα2 (PC 200, 17.59) completely blocks the BHR-induced effects of IL-13 (PC 200, 7.28; P ≤.005). After IL-13 therapy (PC 200, 5.90; P ≤.005), 1 mg/mL of albuterol (PC 200, 3.38; P =.33), fluticasone (PC 200, 4.59; P =.40), or fluticasone plus 50 μg/mL of salmeterol (PC 200, 5.59; P =.11) showed no significant bronchoprotection. In nonsensitized mice, fluticasone plus 0.25 μg/mL of salmeterol (PC 200, 25.90; P ≤.005) showed significantly greater bronchoprotection than did salmeterol alone (PC 200, 11.08; P =.26). Fluticasone plus 0.3 mg/mL of albuterol and fluticasone plus 1 mg/mL of albuterol were significantly more protective than was fluticasone or albuterol alone in ovalbumin-sensitized mice. Conclusions: The protective effects of fluticasone, βagonists, and fluticasone plus β-agonists are significantly less in IL-13-treated mice than in nonsensitized or ovalbumin-sensitized mice.",
author = "Townley, {Robert G.} and Gendapodi, {Pradeep R.} and Nidal Qutna and Joseph Evans and Romero, {Francisco A.} and Abel, {Peter W.}",
year = "2009",
month = "3",
language = "English",
volume = "102",
pages = "190--197",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "3",

}

TY - JOUR

T1 - Effect of interleukin 13 on bronchial hyperresponsiveness and the bronchoprotective effect of β-adrenergic bronchodilators and corticosteroids

AU - Townley, Robert G.

AU - Gendapodi, Pradeep R.

AU - Qutna, Nidal

AU - Evans, Joseph

AU - Romero, Francisco A.

AU - Abel, Peter W.

PY - 2009/3

Y1 - 2009/3

N2 - Background: Fluticasone affects airway bronchial hyperresponsiveness (BHR) and enhances bronchodilation and broncho-protection induced by β-adrenergic agonists. Interleukin 13 (IL-13), however, induces BHR. Objective: To test the hypotheses that fluticasone inhibits BHR after either allergen sensitization or IL-13 administration and that fluticasone restores the bronchodilation and bronchoprotective effects of β-agonists. Methods: The BHR to methacholine induced by IL-13 or ovalbumin was determined in BALB/c mice, and the provocation concentration of methacholine that caused an increase in enhanced pause in expiration of 200% (PC 200) was calculated. We compared this response to methacholine in control mice with the response after treatment with IL-13 receptor α 2-IgGFc fusion protein (IL-13Rα2) (an IL-13 blocker), fluticasone, albuterol, salmeterol, fluticasone-albuterol, and fluticasone-salmeterol. Results: IL-13Rα2 (PC 200, 17.59) completely blocks the BHR-induced effects of IL-13 (PC 200, 7.28; P ≤.005). After IL-13 therapy (PC 200, 5.90; P ≤.005), 1 mg/mL of albuterol (PC 200, 3.38; P =.33), fluticasone (PC 200, 4.59; P =.40), or fluticasone plus 50 μg/mL of salmeterol (PC 200, 5.59; P =.11) showed no significant bronchoprotection. In nonsensitized mice, fluticasone plus 0.25 μg/mL of salmeterol (PC 200, 25.90; P ≤.005) showed significantly greater bronchoprotection than did salmeterol alone (PC 200, 11.08; P =.26). Fluticasone plus 0.3 mg/mL of albuterol and fluticasone plus 1 mg/mL of albuterol were significantly more protective than was fluticasone or albuterol alone in ovalbumin-sensitized mice. Conclusions: The protective effects of fluticasone, βagonists, and fluticasone plus β-agonists are significantly less in IL-13-treated mice than in nonsensitized or ovalbumin-sensitized mice.

AB - Background: Fluticasone affects airway bronchial hyperresponsiveness (BHR) and enhances bronchodilation and broncho-protection induced by β-adrenergic agonists. Interleukin 13 (IL-13), however, induces BHR. Objective: To test the hypotheses that fluticasone inhibits BHR after either allergen sensitization or IL-13 administration and that fluticasone restores the bronchodilation and bronchoprotective effects of β-agonists. Methods: The BHR to methacholine induced by IL-13 or ovalbumin was determined in BALB/c mice, and the provocation concentration of methacholine that caused an increase in enhanced pause in expiration of 200% (PC 200) was calculated. We compared this response to methacholine in control mice with the response after treatment with IL-13 receptor α 2-IgGFc fusion protein (IL-13Rα2) (an IL-13 blocker), fluticasone, albuterol, salmeterol, fluticasone-albuterol, and fluticasone-salmeterol. Results: IL-13Rα2 (PC 200, 17.59) completely blocks the BHR-induced effects of IL-13 (PC 200, 7.28; P ≤.005). After IL-13 therapy (PC 200, 5.90; P ≤.005), 1 mg/mL of albuterol (PC 200, 3.38; P =.33), fluticasone (PC 200, 4.59; P =.40), or fluticasone plus 50 μg/mL of salmeterol (PC 200, 5.59; P =.11) showed no significant bronchoprotection. In nonsensitized mice, fluticasone plus 0.25 μg/mL of salmeterol (PC 200, 25.90; P ≤.005) showed significantly greater bronchoprotection than did salmeterol alone (PC 200, 11.08; P =.26). Fluticasone plus 0.3 mg/mL of albuterol and fluticasone plus 1 mg/mL of albuterol were significantly more protective than was fluticasone or albuterol alone in ovalbumin-sensitized mice. Conclusions: The protective effects of fluticasone, βagonists, and fluticasone plus β-agonists are significantly less in IL-13-treated mice than in nonsensitized or ovalbumin-sensitized mice.

UR - http://www.scopus.com/inward/record.url?scp=63449125724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449125724&partnerID=8YFLogxK

M3 - Article

VL - 102

SP - 190

EP - 197

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 3

ER -